CDK2 Inhibitor Compounds for Selective Cell-Cycle Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds capable of inhibiting the activity of Cyclin-dependent kinase 2 (CDK2) to prevent aberrant DNA replication and treat various disorders related to CDK2 activity, particularly in the context of cancer and other proliferative diseases.
Innovation Solution
Development of compounds that bind and inhibit CDK2/cyclin complexes, specifically targeting CDK2/cyclin E and/or CDK2/cyclin A complexes, to regulate the cell cycle and prevent aberrant DNA replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK2 inhibitors are developed to prevent aberrant DNA replication and treat cancers, then therapeutic efficacy is improved, but drug selectivity and off-target effects become critical challenges
Solution Approach 1:
The patent applies local quality by designing the inhibitor molecule with specific functional groups positioned to interact with unique residues in the CDK2 active site. The compound features a hydroxamic acid group that chelates the catalytic magnesium ions, combined with specific aromatic and aliphatic substituents that form hydrogen bonds and hydrophobic interactions with CDK2-specific amino acid residues, thereby achieving selective inhibition of CDK2 over other CDK isoforms.
Solution Approach 2:
The patent employs the catalytic magnesium ions in the CDK2 active site as an intermediary binding element. The hydroxamic acid group of the inhibitor acts as a mediator that chelates these magnesium ions, forming a stable complex that blocks substrate access to the active site. This magnesium ion-mediated binding mechanism provides high selectivity for CDK2, as the coordination geometry and ion environment are specific to CDK2's active site architecture.
2Stability of the object's composition
If compounds are designed to specifically inhibit CDK2/cyclin complexes, then cell cycle regulation is improved, but compound complexity and synthesis difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a core hydroxamic acid chelating group for magnesium ion binding, an aromatic ring system for hydrophobic and pi-stacking interactions, aliphatic chain segments for hydrogen bonding, and terminal substituents for additional specificity. This modular segmentation allows for systematic optimization of each functional element independently while maintaining overall molecular stability and CDK2 binding affinity.
Solution Approach 2:
The patent employs parameter changes by systematically varying key molecular parameters including the length and substitution pattern of aliphatic chains, the position and type of aromatic substituents, and the oxidation state of the hydroxamic acid group. These parameter optimizations enhance the compound's ability to form stable interactions with CDK2/cyclin complexes while maintaining reasonable synthetic complexity. The balanced molecular weight and logP values achieved through these parameter adjustments also improve pharmacokinetic properties.
Data Source
AI summary
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.